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ABSTRACT 
Purpose: BRAF mutations represents the main negative prognostic factor for metastatic colorectal 
cancer. Right-sided colon cancer (RCC) reported a higher prevalence of BRAF mutations than left-
sided, hence the different response to anti-EGFR targeted therapy in first line setting. Methods: A 
retrospective study of RCC patients, with BRAF known mutation status, treated with chemotherapy 
(CT) from October 2008 to June 2019 in 5 Italian centers, was conducted. Results: We identified 
207 advanced RCC patients: 20.3% BRAF-mutant and 79.7% BRAF wild-type (wt). BRAF-mutant 
cancers were more likely to be pT4 (50.0% v 25.7%, p=0.016), undifferentiated (71.4% v 44.0%, 
p=0.004), KRAS wt (90.5% v 38.2%, p<0.001) and MSI-H (41.7% v 16.2%, p= 0.019) tumors, 
with synchronous (52.4% v 31.5%, p=0.018) and peritoneal metastases ( 38.1% v 22.4%, p=0.003). 
Median overall survival (OS) was 16 vs 27 months in BRAF-mutant and BRAF wt (P = 0.020). In 
first line setting, BRAF-mutant showed a 2y OS of 80% in clinical trials, 32% in anti-VEGF, 14% 
in anti-EGFR and 0% in chemotherapy alone regimens (P = 0.009). BRAF-mutant patients 
demonstrated worse survival, regardless of targeted-therapy administered. However, survival 
difference was statistically significant in the anti-EGFR treated subgroup (16 v 28 months, P = 
0.005 in BRAF mutant v BRAF wt, respectively). Conclusions: Our study demonstrated that 
BRAF status makes the difference in treatment’s outcome. Therefore, the anti-EGFR should not to 
be excluded in all advanced RCC but considered on a case-by-case basis.  
Keywords: colorectal cancer, RCC, sidedness, BRAF, anti-EGFR 
 
 
 
 
 
 
 
 
 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 3 
 
INTRODUCTION 
Colorectal cancer (CRC) is the third most common cancer worldwide [1]. In recent years, the 
sidedness seems to be a well-established and relevant prognostic factor due to distinct differences in 
epidemiology, pathogenesis, genetic and epigenetic alterations, molecular pathways and outcome 
between right and left-side colorectal cancer [2,3]. Anatomically, the right-sided colon cancer 
(RCC), including cecum, ascending, hepatic flexure and two-third proximal transverse, arises from 
the midgut and receives its main blood supply via the superior mesenteric artery, whereas the distal 
colon arises from the hindgut and is supplied by the inferior mesenteric artery.  
Moreover, RCC is prevalent among old age patients with iron deficiency anemia at diagnosis [4] 
and in female gender [5] and is more likely to be diploid and to be characterized by high 
microsatellite instability [6], CpG island methylation, and BRAF mutations [7-10]. 
Patients affected with RCC reported an increased frequency of vascular invasion, mucinous type, 
high grade, invasive tumor border and a higher total number of harvested lymph nodes [11] but with 
lower rates of node positivity [12] than the left-side colon cancer (LCC) [13].  
Furthermore, different signaling pathways are involved in the development of colon cancer: in the 
RCC is more prevalent the serrated pathway [14,15], in which BRAF mutations develop and CpG 
island hypermethylation occurs, resulting in gene transcriptional inactivation and loss of gene 
function by methylation of the promoter region. Otherwise, the conventional pathway with 
mutations in KRAS, TP53, and APC is associated with LCC. 
From this literature data it is clear how the RCC constitutes a different entity than the LCC. All these 
factors may contribute to the difference observed in patient prognosis and to explain the relationship 
between cancer location and mortality. Several population-based studies have explored the prognostic 
relevance of laterality in CRC, with conflicting results [16-20].  
Meguid et al[16] reported that right-sided cancers had a higher risk of mortality than left-sided 
colorectal cancers across all stages (HR, 1.04; 95% CI, 1.02 to 1.07); It was also confirmed by a 
more recent meta-analysis [2] of 66 studies published from 1995 to 2016, showed that LCC were 
associated with improved survival rather than RCC (HR, 0.82; 95% CI, 0.79-0.84). The association 
between RCC and higher mortality is strongest for patients with stage III and IV disease [19]. 
Moreover, the right-sidedness seems to be also a predictive factor of response to first line treatment 
in mCRC patients. A retrospective analysis from CRYSTAL and FIRE-3 trials, in patients with 
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RAS wild-type (wt) mCRC treated with chemotherapy and anti-EGFR targeted agent, found a better 
response in LCC than RCC patients [21]. On the basis of these results, NCCN guidelines 
recommend choosing anti-EGFR plus chemo as first line chemotherapy only in left-sided mCRC 
[22].   
Moreover, as shown by the data of CALGB/SWOG 80405 trial, among patients with KRAS wt 
disease, overall survival (OS) and progression free survival  (PFS) were better in those with left-
sided primary tumors while, both OS and PFS were better with bevacizumab than with cetuximab 
in patients with right-sided primary tumors [23]. However, the NRAS and/or BRAF status was not 
considered.  
In general, BRAF mutations are present in about 10% of colorectal cancer cases but over two-thirds 
of BRAFV600E tumors originate in the RCC vs the LCC (68 vs 32%) [7]. The RCC negative 
prognosis seems to be related with the more frequent BRAF mutations [24,25] which represents the 
main negative prognostic factor for mCRC, regardless of sidedness and other molecular factors 
[26]. Indeed, BRAF-mutant CRC has emerged as a distinct biologic entity, refractory to standard 
chemotherapy regimens approved for the treatment of metastatic CRC and associated with a dismal 
prognosis [27-29]. An effective therapy has not yet been identified although some positive data 
have emerged regarding the use of more intensive chemotherapy backbone plus bevacizumab as 
initial therapy [30] and the more recent multi-targeted therapy combinations [31-34]. Up to date, it 
is still not clear which is the best therapeutic strategy in RCC tumors, albeit with BRAF mutation. 
However, clinical trials with combining MAPK pathway targeted therapies are under investigation 
and could be the best therapeutic strategy [27].  
This is a retrospective analysis of metastatic RCC patients referred to 5 Italian centers with the aim 
to evaluate the outcome of RCC patients according to BRAF status and the treatment performed. 
 
METHODS 
Patients 
A multi-institutional retrospective analysis of clinical data from 207 patients with right mCRC 
treated with chemotherapy from October 2008 to June 2019 was done. All patients with BRAF 
known mutation status were included in this analysis. The study was conducted in accordance with 
the Declaration of Helsinki and Institutional Review Board approval.  
Statistical Analysis  
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 5 
SPSS statistical software, Version 24 (SPSS Inc. Chicago, Illinois, USA) was used. The 2 -test and 
t-test for unpaired data were applied to compare frequencies and means, respectively. The 
interaction among clinicopathologic parameters was first analysed using univariate logistic 
regression. Survival curves were estimated using the Kaplan-Meier method and the log-rank test 
was used for the difference assessment. A multivariate Cox-proportional hazard model was used to 
identify independent prognostic factors for survival. All reported P values are two sided and P 
values less than 0.05 are considered statistically significant.  
 
RESULTS 
Clinicopathological Characteristics 
This study included 207 right-sided metastatic colon cancer patients with known BRAF mutation 
status. All patients’ clinicopathological characteristics are summarized in Table 1. In total 42 
(20.3%) patients had BRAF mutant tumors and 165 (79.7%) had BRAF wt tumors. Also 
KRAS/NRAS and MSI status were considered for the analysis. According to RAS-status, 40 (20%) 
patients undergone a first line chemotherapy with an anti-EGFR target agent. 
Differences in clinicopathological characteristics between BRAF mutant and BRAF wt tumors are 
reported in Table 2. BRAF-mutant RCC was significantly more likely to occur in pT4 (50.0% v 
25.7%, p=0.016), undifferentiated (71.4% v 44.0%, p=0.004) KRAS wt (90.5% v 38.2%, p<0.001), 
MSI-H (41.7% v 16.2%, p= 0.019) tumors,with synchronous (52.4% v 31.5%, p=0.018) and 
peritoneal metastases ( 38.1% v 22.4%, p=0.003).  A higher proportion of BRAF mutant tumors 
was observed in female patients, although this was not statistically significant (52.4% v 47.6% in 
female and male group, respectively). Moreover, the tumor onset with anemia was more common in 
BRAF mutant than BRAF wt tumors (40% v 27.3%, p=0.065) No difference between BRAF status 
was found in right colon tumor location as well as mucinous histology or lymph-nodes 
involvement. 
Survival analysis  
In our study, BRAF mutant RCC showed a poorer prognosis than BRAF wt tumors with a median 
OS of 16.0 (range 13.72 -18.27) vs 27.0 (range 21.82 – 31.17) months, respectively (hazard ratio 
[HR], 1.60; 95% CI, 1.06-2.41; P = 0.020) (Figure 1a) 
Other clinicopathological factors significantly associated with poorer survival included age >70 
years (P = 0.002), pT4 (P = 0.009), pN2 (P = 0.034), G3-4 tumor grading (P = 0.009) and lympho-
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vascular invasion (P = 0.013) at the histological exam. Moreover, peritoneum as metastatic site 
(P=0.040) and the synchronous occurrence of metastases (P = 0.045) were associated with a worse 
survival. On the contrary, a good ECOG PS (P = <0.0001), primary resected tumors (P = <0.0001) 
and the upfront surgery of liver metastases (P = 0.001) were associated with better outcome. At the 
multivariate analysis, only BRAF status, baseline ECOG PS and the upfront surgery of metastatic 
disease were independent prognostic factors of survival (Table 3)  
Overall, there was non-significant difference in median OS between first line treatment with mono 
or doublet chemotherapy (18.0 months, range 10.5 – 25.4), triplet chemo regimen (25.0 months, 
range 18.1 - 31.8), chemo plus an anti-VEGF (24.0 months, range 13- 24.9) or anti-EGFR (26.0 
months, range 20.9 – 31.1)  targeted agent and clinical trials with immunotherapy (not reached) (HR 
= 0.90, 95%CI 0.81-1.00, P = 0.072). (Figure 2a) However, taking into account the first line 
regimen, patients enrolled in clinical trials showed a better median progression free survival (PFS1) 
than others (17.0 v 6.0 v.13.0 months, in clinical trials, CT plus a target agent and triplet CT group, 
respectively) (HR = 0.90, 95%CI 0.82-0.99, P = 0.037). (Figure 2b) Beyond first-line treatment, 
clinical trials and reintroduction of triplet CT regimen performed significantly better than the other 
treatment strategies (median PFS2 was 16.0 v 15.0 v 7.0 v 5.0 v 4.0 v 2.0 months in clinical trials, 
triplet CT, CT plus anti-EGFR, CT plus anti-VEGF, CT alone and regorafenib/lonsurf as second 
line therapy, respectively) (HR = 0.69, 95%CI 0-57-0.85, P = 0.001) (Figure 2c). Although a more 
intensified chemotherapy regimen seems to give more survival benefit, non-significant difference 
was found among third-line treatments (HR for PFS3 = 1.0, 95% CI 0.94-1.07, P = 0.883) (Figure 
2d)  
In a bivariate analysis where BRAF status was stratified by treatments, there was no significant 
survival differences between first line CT with anti-EGFR or anti-VEGF targets in BRAF wt 
tumors (Figure 1b), while, in BRAF mutant tumors, 2ys OS was 80% v 32% v 14% v 0% in clinical 
trials, anti-VEGF, anti-EGFR and CT alone regimen, respectively (HR = 0.63, 95%CI 0.45-0.89, P 
= 0.009) (Figure 1c). In the reverse analysis where anti-EGFR and anti-VEGF based chemotherapy 
were stratified by BRAF status, we demonstrated poorer survival for BRAF mutant tumors 
regardless of targeted-therapy administered even if there was a significantly difference only in the 
subgroup of patients treated with CT plus anti-EGFR target agents, where BRAF mutant showed a 
significant lower OS. (HR for anti-EGFR = 16 v 28 months in BRAF mutant v BRAF wt tumors, P 
= 0.005; HR for anti-VEGF = 18 v 26 months in BRAF mutant v BRAF wt tumors, P = 0.509). 
(Figure 3a. 3b) 
DISCUSSION 
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 7 
By now we know that RCC is a completely different entity with a different embryological origin, 
molecular pathways (harboring BRAF, PIK3CA, and KRAS mutations, more frequently with MSI-
H phenotye) and poorer outcome than LCC [2-15]. Therefore, a better understanding of RCC 
behavior is crucial to explain the different response to chemotherapy and the available targeted 
agents.  
The worse prognosis of RCC is confirmed irrespective of the therapeutic strategy [26, 35, 36] 
although a triplet chemotherapy backbone plus bevacizumab as initial therapy [30] and especially a 
multi-targeted therapy combination seems to be the best future therapeutic choice [31-34].  
We conducted a multi-institutional retrospective analysis of advanced RCC patients with known 
BRAF status and available treatment data with the aim to identify predictive factors for survival and 
the difference between target agents compound in first line chemotherapy choice.  
The proportion of BRAF mutant tumors (42/207 patients) was consistent across this population and 
more large-scale cohorts’ study (57/201 patients), including RCC [7]. According to the recently 
published largest series of V600E BRAF-mutated mCRC [37], our study confirmed a median 
overall survival in BRAF mutant tumors of less than 20 months and significantly worse OS in 
patients with an ECOG PS 1 (P = <0.0001), G3-4 tumor grading (P = 0.009), with lympho-
vascular invasion (P = 0.013), not having the primary tumor resected (P = <0.0001).   
Moreover, according to the largest stage IV colon cancer analysis for survival [17], our study 
showed older age (P = 0.002), pT4 (P = 0.009), pN2 (P = 0.034), peritoneum as metastatic site 
(0.040), and the synchronous occurrence of metastases (P = 0.045), independent of the number of 
metastatic site, as significantly negative prognostic factor of survival. On the contrary, the upfront 
surgery of liver metastases (P = 0.001) was associated with better outcome. 
As previously described [37], BRAF mutant RCC tumors was significantly reported  in pT4 (P = 
0.016), G3-4 tumor grading (P = 0.004) KRAS-wt (P <0.0001), MSI-H (P = 0.019), metachronous 
(P = 0.018), especially peritoneal metastases (P = 0.003). 
 
Several trials on metastatic setting have found worsen outcomes in RCC patients rather than LCC, 
and a different therapeutic response to the anti-EGFR targetd agents [38].  Effectively, a 
chemotherapy doublet or triplet plus bevacizumab was indirectly approved by retrospective, post-
hoc analysis mainly focused on describing differences between RCC and LCC [39-42], as the new 
standard first line chemotherapy for metastatic RCC, regardless of RAS status.  
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 8 
Non-significant difference was found between treatment arms, irrespective of anti-VEGF or anti-
EGFR target agent first line therapy used, although patients enrolled in clinical trials showed a 
better median PFS1 than CT plus target agent as well as triplet CT group (17.0 v 6.0 v.13.0 months, 
respectively). 
RCC patients are characterized by a MSI-high cancer more frequently than LCC [6], and by a 
higher total number of harvested lymph nodes [11] but with lower rates of node positivity [12]. The 
reasons for these node-status differences were both anatomic and molecular: it has been shown as 
the right-sided colon mesentery contains a more complex lymphatic system, leading to an enhanced 
immune response and an increased number of lymph nodes examined after surgey [43,44].In this 
retrospective analysis, a small number of patients with MSI-H phenotype were enrolled in clinical 
trials with an anti-PD1 and actually reported a significant better outcome than patients who were 
not enrolled in clinical trials. (HR for PFS1 = 0.90, 95%CI 0.82-0.99, P = 0.037; HR for PFS2 = 
0.69, 95%CI 0-57-0.85, P = 0.001). 
With regard to the second-line CT, we did not find any differences between anti-VEGF or anti-
EGFR target agents, with the exception of significant better survival in clinical trials and in which 
cases of patients resulted to be fit for reintroduction of triplet CT regimen (median PFS2 was 16.0 v 
15.0 v 7.0 v 5.0 v 4.0 v 2.0 months in clinical trials, triplet CT, CT plus anti-EGFR, CT plus anti-
VEGF, CT alone and regorafenib/lonsurf as second line therapy, respectively) (HR = 0.69, 95%CI 
0-57-0.85, P = 0.001) 
Actually, BRAF mutant RCC patients in this study reported a median OS of 16 months (range 13.7 
-18.3) which was not so far from median OS reported in BRAF-mutant patients enrolled in the 
TRIBE trial [30], with a worse survival than BRAF wt patients, both in anti-VEGF and anti-EGFR 
target agent treatment groups. In the bivariate analysis, where BRAF status was stratified by 
treatments, there was showed non-significant survival differences between first line CT with anti-
EGFR or anti-VEGF targets in both BRAF and RAS wt tumors (28.0 v 26.0 months, respectively. P 
= 0.427) (Figure 1b). But if we looked at only BRAF mutant tumors, 2ys OS was significantly 
higher in clinical trials group (80% v 32% v 14% v 0% in clinical trials, anti-VEGF, anti-EGFR 
plus CT, and CT alone or triplet backbone regimen, respectively; HR = 0.63, 95%CI 0.45-0.89, P = 
0.009) (Figure 1c). At the reverse analysis where anti-EGFR and anti-VEGF based chemotherapy 
were stratified by BRAF status, we demonstrated that BRAF mutant tumors reported a poorer 
survival than BRAF wt tumors, regardless of targeted-therapy administered. However, RAS wt 
tumors treated with CT plus anti-EGFR showed a significant difference in survival according to 
BRAF mutation  (HR for anti-EGFR = 16 v 28 months in BRAF mutant v BRAF wt tumors, P = 
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0.005; HR for anti-VEGF = 18 v 26 months in BRAF mutant v BRAF wt tumors, P = 0.509). 
(Figure 3a. 3b). These data, taking into account the prevalence of BRAF mutation in RCC, may 
explain the more pronounced lower effect in RCC than LCC, reported in post-hoc analysis of 
clinical trials focused on anti-EGFR therapy in the first-line setting [45]. Furthermore, RCC was 
associated with Consensus Molecular Subtypes (CMS) different from LCC [46-48]  and these 
molecular patterns may also explain the different response to targeted agents. Indeed, a 
retrospective analysis of the CALGB/SWOG 80405 which compared the efficacy of Cetuximab v 
Bevacizumab when added to standard first line chemotherapy, found that RAS wt patients with 
CMS1 (mostly RCC patients) benefitted significantly more if they had been randomized to 
Bevacizumab compared to Cetuximab, whereas a trend towards better outcomes was observed for 
CMS2 patients if they had been randomized to Cetuximab. Based on these observations and given 
the real-life results of our analysis, further studies are needed to determine if these molecular 
signatures according to sidedness are crucial predictive markers of response to specific targeted 
agents, and also to definitively answer the question about the best first line chemotherapy in RAS-
wt, BRAF-mutant, RCC patients.  
 
CONCLUSIONS  
Advanced RCC is a different entity from LCC, with a significant correlation with known negative 
prognostic factors such as advanced pT and pN stage, dedifferentiated tumor grading, metachronous 
and peritoneal metastases. All these clinicopathological factors may contribute to the difference 
observed in patient’s prognosis with increasing pooled data demonstrating a shorter survival for 
patients with RCC than LCC tumors. Although the limit of sample size, our study demonstrated that 
BRAF status makes the difference for treatment response. Therefore, a first-line CT plus an anti-
EGFR targeted agent should not to be excluded in all RCC cases in advance but considered on a 
case-by-case basis. Meanwhile, RCC patient with BRAF mutant tumors or with MSI-H phenotype, 
who do not respond to standard treatment, should be more much deemed to be enrolled in clinical 
trials. Certainly, a better knowledge of the main specific predictive factors in selected subgroups of 
RCC patients and prospective clinical trials stratifying participants according to primary tumor 
location would be very useful for helping physician in the future therapeutic algorithm choice.  
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Figure Captions 
 
Fig. 1a-c Overall survival (OS) according to BRAF status (a). OS in BRAF wild-type tumors (b) 
and BRAF mutant tumors (c) according to first line chemotherapy performed.   
Fig. 2a-d Study population OS according to first line chemotherapy performed (a). Progression free 
survival according to first line (PFS1) (b), second line (PFS2) (c) and third line (PFS3) therapy (d).  
Fig. 3a-b The reverse analysis of OS where anti-EGFR (a) and anti-VEGF (b) based therapies were 
stratified by BRAF status.  
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Table 1. All clinicopathologic features (valid cases and percentages)  
 N.  % 
Total 207 100 
Age  
Median (range) 
 
66 (38-86) 
Age category 
 70 
>70 
 
127 
80 
 
61.4 
38.6 
Sex 
Male 
Female 
 
126  
81  
 
60.9 
39.1 
Charlson Comorbidity Index 
 8 
> 8 
Not available 
 
104 
96 
7 
 
50.2 
46.4 
3.4 
Tumor onset  
Anemia  
Intestinal occlusion 
Pain  
Intestinal perforation 4 
other (fever, weight loss, asthenia)  
 
50 
42 
13 
4 
54 
 
24.2 
20.3 
6.3 
1.9 
26.1 
Primary tumor resected 
Yes 
No 
 
45 
162 
 
21.7 
78.3 
Tumor location 
Ascending and proximal hepatic flexure  
Cecum  
Distal hepatic flexure and two-third 
proximal transverse  
 
90 
70 
47 
 
43.5 
33.8 
22.7 
pT 
 3 
4 
 
100 
45 
 
48.3 
21.7 
pN 
0 
1 
2 
 
35 
47 
67 
 
16.9 
22.7 
32.4 
Lymphovascular/perineural Invasion 
Yes 
No 
 
87 
42 
 
20.3 
42.0 
Tumor Grading 
G1 – 2 
 
85 
 
41.1 
Table 1
G3 - 4 84 40.6 
Mucinous Histology 
Yes 
No 
 
60 
140 
 
29.0 
67.6 
KRAS 
Wild-type  
Mutated 
 
101 
106 
 
48.8 
51.2 
NRAS 
Wild-type 
Mutated 
 
128 
7 
 
61.8 
3.4 
BRAF 
Wild-type 
Mutated  
 
165 
42 
 
79.7 
20.3 
Microsatellite Instability 
MSS 
MSI-High 
 
66 
19 
 
31.9 
9.2 
Baseline ECOG Performance status  
0 
1 
 
149 
58 
 
72.0 
28.0 
Adjuvant chemotherapy 
Yes 
No 
 
51 
156 
 
24.6 
75.4 
Adjuvant oxaliplatin 
Yes 
 
43 
 
20.7 
Upfront treatment of liver metastases  
Surgery 
RFA/TACE  
 
49 
10 
 
23.7 
4.8 
Presentations of metastases 
Synchronous 
Metachronous 
 
133 
74 
 
64.3 
35.7 
Site of metastases at diagnosis 
Liver 
Lung 
Peritoneum 
Local relapse 
Distant nodes  
 
122 
22 
53 
7 
3 
 
58.9 
10.6 
25.6 
3.4 
1.4 
N. of metastatic sites 
1 
 2 
 
81 
126 
 
39.1 
60.9 
First line Chemotherapy (CT) regimen 
CT alone (mono/doublet regimen) 
 
38 (6/32) 
 
18.4 (2.9/15.5) 
CT plus anti-VEGF 
CT plus anti-EGFR 
Triplets CT (plus anti-VEGF/anti-EGFR) 
Clinical Trials 
No CT 
80 
38 
38 (13/2) 
5 (5) 
7 
39.0 
18.4 
18.4 (6.3/1.0) 
2.4 
3.4 
Second Line  
CT alone (mono/doublet regimen) 
CT plus anti-VEGF (Bevacizumab/Aflibercept) 
CT plus anti-EGFR 
Triplets CT (plus anti-VEGF/anti-EGFR) 
Clinical trials 
Regorafenib 
Tas102 
 
33 (9/24) 
68 (46/22)  
5 
9 (2/0) 
9 
3 
1 
 
15.9 (7.0/18.8) 
53.2 (22.2/10.6) 
2.4 
4.3 (1.0/0) 
4.3 
1.5 
0.5 
Third Line  
CT alone (mono/doublet CT) 
CT plus anti-VEGF 
CT plus anti-EGFR 
Triplets CT (plus anti-VEGF/anti-EGFR) 
Clinical Trials 
Regorafenib 
Tas 102 
 
25 (11/14) 
7 
2 
4(2/0) 
3 
17 
5 
 
12.1 (5.3/6.8) 
3.4 
1.0 
1.9 (1.0/0) 
1.5 
8.2 
2.4 
Beyond 3-line Treatment 
Yes/Rechallange  
 
35/19 
 
16.9/9.2 
Abbreviations : RFA: radiofrequency ablation, TACE: transarterial chemoembolization 
Table 2. Clinicopathologic parameters distribution between BRAF-wild type (wt) and BRAF-mutant tumors  
 BRAF-wt BRAF-mutant  P 
Total N (%) N (%)  
Age category 
 70 
>70 
 
102 (61.8) 
63 (38.2) 
 
25 (59.5) 
17 (40.5) 
 
 
0.860 
Sex 
Male 
Female 
 
105 (63.6)  
60 (36.4)  
 
20 (47.6) 
22 (52.4) 
 
 
0.077 
Charlson Comorbidity Index 
 8 
> 8 
 
80 (49.7) 
81 (50.3) 
 
24 (61.5) 
15 (38.5) 
 
 
0.213 
Tumor onset  
Anemia  
Intestinal occlusion 
Pain  
Intestinal perforation  
other (fever, weight loss, asthenia)  
 
35 (27.3) 
33 (25.8) 
14 (10.) 
4 (3.1) 
42 (32.8) 
 
14 (40.0) 
9 (25.7) 
0 (0.0) 
0 (0.0) 
12 (34.3) 
 
 
 
0.171 
Primary tumor resected 
Yes 
No 
 
129 (78.2) 
36 (21.8) 
 
33 (78.6) 
9 (21.4) 
 
 
1.000 
Tumor location 
Ascending and proximal hepatic flexure  
Cecum  
Distal hepatic flexure and two-third 
proximal transverse 
 
69 (41.8) 
60 (36.4) 
36 (21.8) 
 
21 (50.0) 
10 (23.8) 
11 (26.2) 
 
 
0.308 
pT 
 3 
4 
 
84 (74.3) 
29 (25.7) 
 
16 (50.0) 
16 (50.0) 
 
 
0.016 
pN 
0 
1 
2 
 
28 (24.1) 
39 (33.6) 
49 (42.2) 
 
7 (21.2) 
8 (24.2) 
18 (54.5) 
 
 
0.433 
Lymphovascular/perineural Invasion 
Yes 
No 
 
64 (65.3) 
34 (34.7) 
 
23 (74.2) 
8 (25.8) 
 
 
0.389 
Tumor Grading 
G1 – 2 
G3 - 4 
 
75 (56.0) 
59 (44.0) 
 
10 (28.6) 
25 (71.4) 
 
 
0.004 
Mucinous Histology 
Yes 
 
43 (27.2) 
 
16 (38.1) 
 
0.185 
Table 2
No 115 (72.8) 26 (61.9) 
KRAS 
Wt 
mut 
 
63 (38.2) 
102 (61.8) 
 
38 (90.5) 
4 (9.5) 
 
 
<0.0001 
NRAS 
Wt 
Mut 
 
90 (93.8) 
6 (6.3) 
 
38 (97.4) 
1 (2.6) 
 
0.673 
Microsatellite Instability 
MSS 
MSI-H 
 
57 (83.8) 
11 (16.2) 
 
9 (52.9) 
8 (47.1) 
 
 
0.019 
Baseline ECOG Performance status 
0 
1 
 
117 (70.9) 
48 (29.1) 
 
32 (76.2) 
10 (23.8) 
 
 
0.567 
Presentations of metastases 
Synchronous 
Metachronous 
 
113 (68.5) 
52 (31.5) 
 
20 (47.6) 
22 (52.4) 
 
 
0.018 
Site of metastases at diagnosis 
Liver 
Lung 
Peritoneum 
Local relapse 
Distant nodes  
 
101 (61.2) 
22 (13.3) 
37 (22.4) 
4 (2.4) 
1 (0.6) 
 
21 (50.0) 
0 (0.0) 
16 (38.1) 
3 (7.1) 
2 (4.8) 
 
 
 
0.003 
 
 
N. of metastatic sites 
1 
 2 
 
60 (36.4) 
105 (63.6) 
 
21 (50.0) 
21 (50.0) 
 
 
0.114 
 
Table 3. The correlation between clinicopathological factors and overall survival (OS) of study Patients  
Factors  Univariate analysis Multivariate analysis 
 OS 
(months) 
HR (95% CI) P  HR (95% CI) P value 
Age >70 v 70 ys 19 v 31 1.73 (1.22-2.46) 0.002 1.35 (0.78-2.35) 0.274 
Sex Male v Female 25 v 21 0.97 (0.69-1.37) 0.881   
CCI >8 v 8 23 v 27 1.28 (0.90-1.81) 0.159   
Onset with Anemia v 
intestinal symptoms  
19 v 27 1.39 (0.83-2.33) 0.199   
Cecum v ascending v 
transverse colon cancer  
22 v 23 v 
27 
1.01(0.89-1.15) 0.824   
pT 4 v 3 19 v 40 1.82 (1.16-2.86) 0.009 1.37 (0.76-2.44) 0.287 
pN 2 v 1 v 0 21 v 41 v 
43 
1.34 (1.02-1.77) 0.034 1.11 (0.77-1.59) 0.563 
Mucinous histology YES v 
NO 
26 v 24 0.95 (0.65-1.39) 0.823   
Grading 3-4 v 1-2 19 v 32 1.65 (1.13-2.42) 0.009 0.93 (0.52-1.65) 0.810 
LVI YES v NO 23 v 43 1.84 (1.13-2.98) 0.013 1.57 (0.88-2.82) 0.126 
KRAS mut v wt 23 v 26 0.97 (0.69-1.37) 0.896   
NRAS mut v wt  14 v 25 1.62 (0.58-4.47) 0.350   
BRAF mut v wt  16 v 27 1.60 (1.06-2.41) 0.020 1.97 (1.02-3.81) 0.043 
MSI-H v MSS 41 v 28 0.60 (0.29-1.32) 0.231   
Surgery of primary tumor 
YES v NO 
31 v 16  0.38 (0.25-0.57) <0.0001 1.08 (0.32-3.65) 0.181  
Baseline ECOG PS 1-2 v 0 16 v 31 2.09 (1.4-3.0) <0.0001 1.74 (1.02-2.96) 0.040 
Metachronous v 
synchronous metastases 
33 v 21  0.68 (0.47-0.99) 0.045 0.72 (0.43-1.29) 0.273 
Metastases of peritoneum 
v others 
20 v 26 1.22 (1.1-1.46) 0.040 1.29 (0.96-1.73) 0.084 
N. of Metastatic site 2 v 1 21 v 31 1.41 (0.99-2.01) 0.054   
Upfront surgery of liver 
metastases Yes v No 
43 v 20  0.46 (0.30-0.71) 0.001 0.37 (0.20-0.67) 0.001 
Abbreviations: CCI: charlson comorbidity index; LVI: lymphovascular invasion; PS: performance status  
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Study population Overall Survival (OS) 
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